Health checkups · patient guide

CA-125 blood test in China explained

CA-125 is a protein measured in a blood sample. It is used mainly to monitor known ovarian cancer and to investigate certain symptoms, not to prove or exclude cancer by itself. In China the test is ordered by a clinician, and the number only means something alongside your history, examination and imaging. Ask the treating team what your result is being compared against.

Go to the practical guidance ↓
AI illustration: Two women having a consultation at a desk with documents and plants in the background.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

What the CA-125 test actually measures

CA-125 (cancer antigen 125) is a protein that can be detected in blood. The test reports its concentration. It is not a test that detects ovarian cancer directly; it measures a marker that can rise for several different reasons. That distinction matters for anyone considering the test while planning care in China, because the result is interpreted, not simply read off a report.

The marker is best established in following patients who already have a diagnosis of ovarian cancer, where a rising or falling level can contribute to assessing response or recurrence alongside imaging and clinical review. In someone without a known cancer, a raised CA-125 is non-specific. It can be associated with benign conditions and with other situations that irritate the tissue lining the abdomen, and it can also be normal in people who do have ovarian cancer. A normal result therefore does not rule cancer out, and a raised result does not confirm it.

Because of this, clinicians do not generally use CA-125 alone to screen people without symptoms. Guidance from professional bodies has long advised against using it as a stand-alone screening test in the general population. If you have symptoms that concern you, the useful step is a clinical assessment, not a self-ordered marker. The treating clinician decides whether CA-125 belongs in your work-up and what it should be compared with.

Cancer care in China for international patients

Why a single number cannot answer the cancer question

Patients often arrive with a report showing one CA-125 value and a single question: do I have cancer? That question cannot be answered from the number alone. Interpretation depends on your age, whether you still have ovaries or a uterus, your menstrual status, recent surgery or procedures, pregnancy, and conditions such as endometriosis, pelvic infection or liver disease. Each of these can influence the marker, and the treating team needs that context before drawing any conclusion.

The pattern over time is often more informative than one measurement. A value that changes across repeated tests, read together with imaging and symptoms, tells a clinician something different from an isolated result. This is why the same number can mean different things in two patients, and why a clinician may ask for a repeat test, an ultrasound, or a referral rather than acting on the first result.

If you have a known ovarian cancer diagnosis, CA-125 is usually interpreted as part of your overall picture: scan findings, symptoms, examination and treatment history. It is not a substitute for those. Ask your treating team which comparison they are using, whether the same laboratory will process repeat samples, and how they want the trend documented. Those questions are more useful than searching for a threshold that applies to everyone, because no single cut-off separates cancer from non-cancer across all patients.

How testing is arranged for an international patient in China

In China, a CA-125 test is a laboratory test requested by a clinician. A stand-alone diagnostic test normally needs a specialist's order, so the practical route is a consultation with an appropriate specialist, such as a gynaecologist or an oncologist, who reviews your history and decides what testing is appropriate. You should not assume that walking into a laboratory and requesting the test is the standard route; confirm the process with the specific hospital you plan to use.

For an overseas patient, the first useful step is usually a records-based conversation. Bring what you already have: previous CA-125 results with dates and the laboratory that produced them, any imaging reports, pathology reports if a diagnosis exists, a list of your medicines, and a short summary of your symptoms and menstrual history where relevant. A clinician can then say whether the test adds information, whether existing results are sufficient, and what else should be reviewed.

Practical questions to put to the hospital before you travel include: who will order the test, whether an interpreter is needed for the consultation, how results are communicated to you, and whether the report will be issued in a language you can use with your home clinician. These are administrative points that vary between hospitals, so ask the named provider rather than relying on general assumptions. If you are considering a broader checkup rather than a symptom assessment, note that a clinician should advise which tests are suitable; a screening package is not a substitute for investigating a specific concern.

Reading a result alongside your own clinician

When your result arrives, resist the urge to interpret it in isolation. Ask the clinician who ordered it three things: what this value means in the context of my history, what the reference range for this laboratory is, and what the next step should be. Reference ranges can differ between laboratories and assays, so a number that looks alarming against one range may sit differently against another. The report should state the range used; if it does not, ask.

If the result is raised, the next step is usually further assessment rather than immediate conclusions. That may include a repeat test, a pelvic ultrasound, a review of symptoms, or referral to a gynaecological specialist. If the result is normal but you have persistent symptoms, that does not close the question; symptoms still need clinical assessment. The clinician, not the report alone, decides what the pattern means and whether more investigation is warranted.

If you already have a cancer diagnosis and are being monitored, ask how this result fits with your imaging and treatment plan, and whether your treating team wants the sample repeated at the same laboratory for consistency. Keep copies of every result with its date and the laboratory name. A clear record of the trend is more useful to any clinician than a single value remembered out of context.

What a records-based opinion can and cannot settle

An overseas patient may want a specialist in China to review existing records before deciding whether to travel. That kind of records-based opinion can help clarify whether the existing CA-125 results and imaging are sufficient, what additional assessment might be appropriate, and which specialty should see you. It is a review of the information available, not a final diagnosis, and it does not establish hospital acceptance or treatment eligibility.

Be clear about the limits. A remote review cannot examine you, cannot perform an ultrasound, and cannot replace a face-to-face assessment where one is needed. If the records are incomplete, the reviewer should say what is missing rather than guess. A review may conclude that the question is best answered locally, or that a particular test or appointment is the sensible next step. Those are legitimate outcomes, not failures of the process.

For complex cases involving more than one specialty, a multidisciplinary review may be arranged, with the scope and fee agreed beforehand. This is a coordination route, not a clinical decision made by a coordinator. The treating clinicians remain responsible for interpreting results, recommending tests and deciding on care. Ask what the review will cover and what it will not, so your expectations match what is actually being offered.

Symptoms that should not wait for a test result

A blood test is not a reason to delay assessment of symptoms that worry you. Persistent bloating, pelvic or abdominal pain, changes in bowel or bladder habits, unexplained weight loss, or a feeling of fullness that does not settle deserve prompt clinical attention, wherever you are. If symptoms are severe or worsening, seek local medical care rather than waiting to arrange a test abroad. Overseas planning should follow, not replace, urgent assessment.

For anyone with a known ovarian cancer diagnosis, new or worsening symptoms should be discussed with your treating team without waiting for the next scheduled marker test. The marker is one part of monitoring, not a substitute for reporting how you feel. If you are between appointments and unsure whether a symptom is significant, contact your clinical team and describe it; they can advise whether you need to be seen sooner.

This is also where the boundaries of coordination services sit. A coordinator can help arrange appointments, interpretation and practical support, but cannot assess symptoms, interpret a result or advise on treatment. Those decisions belong to licensed clinicians. If you are unsure which specialist to see, a brief initial enquiry can help identify the relevant next step, but it does not replace clinical advice.

A practical next step

If you are considering a CA-125 test in China, start with a short summary of your situation: your main question, any existing results with dates, relevant imaging or pathology reports, and your symptoms. An initial enquiry is free and does not commit you to buying a proxy consultation or any other service. Our team can check what information is available, point out what is missing, and suggest the relevant next step, while the treating hospital and its clinicians decide on testing, interpretation and suitability.

Keep your expectations practical. The test itself is straightforward; the value comes from how the result is interpreted by a clinician who knows your history. Bring your records, ask what the result will be compared against, and let the clinical team guide the decisions that follow.

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Cancer care in China for international patients
  2. procedures

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.